The impact of therapy with TNF-blockers on health-related quality of life in rheumatoid arthritis patients. A pilot study;Calidad de vida relacionada con la salud tras terapia anti-factor de necrosis tumoral alfa en pacientes con artritis reumatoide. Un estudio piloto

Reumatologia Clinica

Volumn 7, Issue 3, 2011, Pages 167-171

  Ábalos Medina, Gracia María ^a   Ruiz Villaverde, Gonzalo ^b   Sánchez Cano, Daniel ^a   Ruiz Villaverde, Ricardo ^c   Ramírez Rodrigo, Jesús ^d   Raya Álvarez, Enrique ^a   Villaverde Gutiérrez, Carmen ^d  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c Hosp Univ Ciudad de Jaén   (Spain)

^d UNIVERSITY OF GRANADA   (Spain)

Author keywords

Quality of life; Rheumatoid arthritis; TNF blocker therapy

Indexed keywords

ETANERCEPT; INFLIXIMAB;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; HUMAN; MALE; PILOT STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SHORT FORM 36; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953796072     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2010.06.004     Document Type: Article

References (22)

1. Vander Cruyssen B., Van Looly S., Wyns B., Westhovens R., Durez P., Van den Bosch F., et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-tanding refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther. 2006, 8:R112.
2. Smolen J.S., Van der Heijde D.M., St Clair E.W., Emery P., Bathon J.M., Keystone E., et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006, 54:702-710. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) study group.
3. Carbonell J., Badia X. Expectativas, preferencias y satisfacción de los pacientes con artritis reumatoide en tratamiento con infliximab. Med Clin (Barc). 2008, 131:493-499.
4. Irvine E.J. Quality of life issues in patient with inflammatory bowel disease. Am J Gastroenterol. 1997, 92:18S-24S.
5. Badía X. La medida de la calidad de vida relacionada con la salud en los ensayos clínicos. Farmacoeconomía: evaluación económica de los medicamentos. 1995, 51-76. Editores médicos, Madrid. J.A. Sacristán, X. Badía, J. Rovira (Eds.).
6. Badía X. Sobre la adaptación transcultural de medidas de la calidad de vida relacionada con la salud para su uso en España. Med Clin (Barc). 1995, 105:56-58.
7. Monés Xiol J. Quality of life. Can it really by measured?. Rev Esp Enferm Dig. 2000, 92:349-353.
8. López-Olivo M.A., Kallen M.A., Ortiz Z., Skidmore B., Suarez-Almazor M.E. Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in reumatoid arthritis: a systematic review. Arthritis Rheum. 2008, 59:1625-1638.
9. Segal B., Rhodus N.L., Patel K. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid artritis. Medical management and pharmacology update. 2008, 106:778-787.
10. Arenere Mendoza M., Manero Ruiz F.J., Carrera Lasfuentes P., Navarro Aznárez H., Pecondón Español A., Rabanaque Hernández M.J. Estudio comparativo de efectividad de los inhibidores del factor de necrosis tumoral alfa en la artritis reumatoide establecida. Med Clin (Barc). 2010, 134:665-670.
11. Van Gestel A.M., Haagsma C.J. Validation of rheumatoid arthritis improvement criteria including simplified joint counts. Arthritis Rheum. 1998, 41:1845-1850.
12. Wells G., Becker J.C., Teng J., Dougados M., Schiff M., Smolen J., et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009, 68:954-960.
13. Alonso J., Prieto L., Antó J.M. La versión española del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de resultados clínicos. Med Clin (Barc). 1995, 104:771-776.
14. Felson D.T., Anderson J.J., Boers M., Bombardier C., Chernoff M., Fried B., et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993, 36:729-740.
15. Danao L.L., Padilla G.V., Johnson D.A. An english and spanish quality of life measure for rheumatoid arthritis. Arthritis Care Res. 2001, 45:167-173.
16. Ballina F. Medición de la calidad de vida en la artritis reumatoide. Reumatol Clin (Barc). 2002, 29:56-64.
17. Han C., Smolen J.S., Kavanaugh A., van der Heijde D., Braun J., Westhovens R., et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther. 2007, 9:R103.
18. Singh J.A., Christensen R., Wells G.A., Suarez-Almazor M.E., Buchbinder R., Lopez-Olivo M.A., et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009, 181:787-796.
19. Wasserman M.J., Weber D.A., Guthrie J.A., Bykerk V.P., Lee P., Keystone E.C., et al. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol. 2004, 31:1912-1917.
20. Fernández Lisón L.C., Vázquez Domínguez B., Luis Fernández J., Moreno Álvarez P., Fruns Giménez I., Liso Rubio J. Calidad de vida en pacientes con artritis reumatoide en tratamiento ambulatorio con anti-TNF. Farm Hosp. 2008, 32:178-181.
21. Gülfe A., Kristensen L.E., Saxne T., Jacobsson L.T., Petersson I.F., Geborek P. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden. Ann Rheum Dis. 2010, 69:352-357.
22. Ogawa H., Itokazu M., Ito Y., Matsumoto K., Takigami I. Quality of life evaluated by Short Form-8 in patients with rheumatoid arthritis who were receiving infusion of infliximab. Mod Rheumatol. 2009, 19:27-32.